Tirzepatide GLP-2 TZ (15 mg Vial) Dosage Protocol
Tirzepatide is a dual GLP-1/GIP receptor agonist studied for type-2 diabetes and chronic weight management. SURMOUNT-1 reported up to 22.5% body-weight reduction at the 15 mg weekly dose. This page covers the 15 mg vial.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
The same published weekly escalation schedule converted for a 15 mg vial
Standard Weekly Escalation Schedule (2 mL = 7.5 mg/mL)
| Study Phase | Weekly Amount | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 33.33 units | 0.3333 mL |
| Weeks 5 to 8 | 5 mg | 66.67 units | 0.6667 mL |
| Weeks 9 to 12 | 7.5 mg | 100 units | 1 mL |
| Weeks 13 to 16 | 10 mg | 133.33 units | 1.3333 mL |
| Weeks 17 to 20 | 12.5 mg | 166.67 units | 1.6667 mL |
| Weeks 21+ | 15 mg | 200 units | 2 mL |
Reconstitution Steps
- Clean the vial stopper and gather the sterile supplies required by the research procedure.
- Add 2 mL of the documented sterile diluent slowly down the vial wall.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial 7.5 mg/mL with the preparation date and follow the exact product storage and discard instructions.
The weekly amounts remain identical across the Tirzepatide family. The 15 mg vial changes only concentration, U-100 units, volume, and supply calculations.
Supplies Needed
Clear 12-week and 24-week planning for a 15 mg vial at 7.5 mg/mL.
| Item | 12-week schedule | 24-week schedule |
|---|---|---|
| Tirzepatide vials (15 mg each) | 4 vials needed. Total scheduled amount: 60 mg. | 14 vials needed. Total scheduled amount: 210 mg. |
| U-100 insulin syringes (1 mL capacity) | 12 new syringes needed. | 36 new syringes needed. |
| Documented sterile diluent (10 mL bottles) | 1 bottle needed. Total diluent volume: 8 mL. | 3 bottles needed. Total diluent volume: 28 mL. |
| Alcohol swabs | 24 swabs minimum. 1 box of 100 covers this minimum. | 60 swabs minimum. 1 box of 100 covers this minimum. |
Sharps disposal: One appropriately sized container for used syringes.
Stability planning: Vial, syringe, swab, and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Tirzepatide is a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors with a single molecule. GLP-1 activation slows gastric emptying, increases satiety, and stimulates glucose-dependent insulin secretion. GIP activation augments insulin secretion further and modulates fat-cell metabolism.
The molecule is fatty-acid acylated to bind albumin and persist in circulation for once-weekly dosing.
Potential Benefits & Side Effects
Potential Benefits
- SURMOUNT-1: 20.9% weight reduction at 15 mg weekly over 72 weeks vs 3.1% placebo.
- SURPASS-2 (T2DM): HbA1c reduction up to 2.46% at 15 mg.
- Greater outcomes than single-agonist comparators in head-to-head trials.
- Improvement in lipid profile and waist circumference reported alongside weight loss.
Side Effect Profile
- Nausea (most common, dose-dependent).
- Diarrhea and vomiting (more common at higher doses).
- Decreased appetite (intended effect).
- Constipation in some users.
- Rare: pancreatitis, gallbladder events.
Lifestyle Factors
- Aggressive hydration — incretin agonists blunt thirst sensation.
- Protein 1.0–1.6 g/kg/day preserves lean mass during weight loss.
- Resistance training 2–3×/week mitigates muscle loss in caloric deficit.
- Avoid high-fat or large-volume meals around dosing.
- Pace meals slowly; eat to 80% fullness rather than past it.
Injection Technique
- Inject subcutaneously into abdomen (away from navel), outer thigh, or upper arm.
- Rotate sites with each weekly dose.
- 90° angle with short insulin needles (4–8 mm).
- Bring vial to room temperature 15 min before injecting.
- Hold 5 seconds after full plunger depression before withdrawing.